BioCentury | Apr 15, 2013
Company News

Neoprobe sales and marketing update

...NEOP began selling the Neoprobe 1500 Portable Radioisotope Detector, a hand-held device that detects gamma rays...
...radiopharmaceutical. NEOP will sell the product through its 14-member sales team. Average price is $34,000. Neoprobe Corp....
BioCentury | Apr 15, 2013
Clinical News

Neoprobe regulatory update

...patent. The peptides are in various stages of testing to surgically detect and treat cancer. Neoprobe Corp....
BioCentury | Apr 15, 2013
Clinical News

Neoprobe regulatory update

...which combines cancer-specific targeting agents. The product is designed to find hidden tumors during surgery. Neoprobe Corp....
BioCentury | Apr 15, 2013
Company News

Neoprobe management update

Neoprobe Corp. (NEOP), Dublin, Ohio Business: Cancer, Diagnostics/Imaging Hired: Larry Anderson, as VP and managing director, Europe; formerly first partner-in-charge of audit of Coopers & Lybrand L.L.P. in Russia WIR Staff cancer Diagnostic...
BioCentury | Jan 21, 2013
Company News

Navidea, AstraZeneca deal

...amyloid imaging agents - AZD2184 and AZD2995 - to a 2011 deal granting Navidea (formerly Neoprobe Corp....
BioCentury | Apr 9, 2012
Clinical News

Lymphoseek tilmanocept regulatory update

...extended the PDUFA date by 90 days for diagnostic product Lymphoseek tilmanocept from Navidea (formerly Neoprobe Corp....
BioCentury | Apr 4, 2012
Company News

FDA delays Lymphoseek decision

...mapping. The new date is Sept. 10; it was June 10. According to Navidea (formerly Neoprobe Corp....
BioCentury | Jan 9, 2012
Financial News

Navidea completes private placement of convertible notes and warrants

...Capital Note: The 30-month secured note bears interest at a prime-based variable rate. Navidea (formerly Neoprobe Corp....
BioCentury | Dec 19, 2011
Company News

Neoprobe, AstraZeneca deal

...AstraZeneca granted Neoprobe exclusive, worldwide rights to AZD4694 , a late-stage radiopharmaceutical imaging agent that binds...
...in clinical and regulatory submission milestones and an additional $11 million upon approval, plus royalties. Neoprobe...
...AstraZeneca retains rights to use AZD4694 in clinical trials to support development of AD treatments. Neoprobe Corp....
BioCentury | Oct 24, 2011
Finance

Highlights of weekly biotech stock moves

...BF-200 ALA ) to treat actinic keratosis. Biofrontera gained €0.66 (20%) for the week. Neoprobe Corp....
Items per page:
1 - 10 of 186
BioCentury | Apr 15, 2013
Company News

Neoprobe sales and marketing update

...NEOP began selling the Neoprobe 1500 Portable Radioisotope Detector, a hand-held device that detects gamma rays...
...radiopharmaceutical. NEOP will sell the product through its 14-member sales team. Average price is $34,000. Neoprobe Corp....
BioCentury | Apr 15, 2013
Clinical News

Neoprobe regulatory update

...patent. The peptides are in various stages of testing to surgically detect and treat cancer. Neoprobe Corp....
BioCentury | Apr 15, 2013
Clinical News

Neoprobe regulatory update

...which combines cancer-specific targeting agents. The product is designed to find hidden tumors during surgery. Neoprobe Corp....
BioCentury | Apr 15, 2013
Company News

Neoprobe management update

Neoprobe Corp. (NEOP), Dublin, Ohio Business: Cancer, Diagnostics/Imaging Hired: Larry Anderson, as VP and managing director, Europe; formerly first partner-in-charge of audit of Coopers & Lybrand L.L.P. in Russia WIR Staff cancer Diagnostic...
BioCentury | Jan 21, 2013
Company News

Navidea, AstraZeneca deal

...amyloid imaging agents - AZD2184 and AZD2995 - to a 2011 deal granting Navidea (formerly Neoprobe Corp....
BioCentury | Apr 9, 2012
Clinical News

Lymphoseek tilmanocept regulatory update

...extended the PDUFA date by 90 days for diagnostic product Lymphoseek tilmanocept from Navidea (formerly Neoprobe Corp....
BioCentury | Apr 4, 2012
Company News

FDA delays Lymphoseek decision

...mapping. The new date is Sept. 10; it was June 10. According to Navidea (formerly Neoprobe Corp....
BioCentury | Jan 9, 2012
Financial News

Navidea completes private placement of convertible notes and warrants

...Capital Note: The 30-month secured note bears interest at a prime-based variable rate. Navidea (formerly Neoprobe Corp....
BioCentury | Dec 19, 2011
Company News

Neoprobe, AstraZeneca deal

...AstraZeneca granted Neoprobe exclusive, worldwide rights to AZD4694 , a late-stage radiopharmaceutical imaging agent that binds...
...in clinical and regulatory submission milestones and an additional $11 million upon approval, plus royalties. Neoprobe...
...AstraZeneca retains rights to use AZD4694 in clinical trials to support development of AD treatments. Neoprobe Corp....
BioCentury | Oct 24, 2011
Finance

Highlights of weekly biotech stock moves

...BF-200 ALA ) to treat actinic keratosis. Biofrontera gained €0.66 (20%) for the week. Neoprobe Corp....
Items per page:
1 - 10 of 186